



#6

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Focke, et al.

Appl. No.: 10/026,911

Filed: December 27, 2001

For: Allergy Vaccines And Their Preparation

Atty. Docket No: 0273-0005

Examiner: To Be Assigned

Group Art Unit: 1614

## PETITION FOR EXTENSION OF TIME UNDER 37 C.F.R. § 1.136

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

It is hereby requested that the period for responding to the outstanding Notice To File Missing Parts Of Nonprovisional Application be extended four months from March 28, 2002 to July 28, 2002 by the filing of this Petition and fee payment.

The petition fee (37 C.F.R. § 1.17) is believed to be \$720.00 for a four-month extension for a small entity. Fee payment is included in our accompanying check. However, if extensions of time under 37 C.F.R. § 1.136 other than those provided herewith are required to prevent abandonment of the present patent application, then such extensions of time are hereby petitioned.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0622.

Respectfully submitted,

SHANKS &amp; HERBERT

07/26/2002 EAREGAY1 00000034 10026911

05 FC:218

720.00 DP

By:

Toni Junell Herbert

Reg. No. 34,348

Date:

7/24/02

TransPotomac Plaza  
1033 N. Fairfax Street  
Suite 306  
Alexandria, VA 22314



A DOCPHOENIX

## APPL PARTS

IMIS \_\_\_\_\_  
Internal Misc. Paper  
LET. \_\_\_\_\_  
Misc. Incoming Letter

371P \_\_\_\_\_  
PCT Papers in a 371 Application

A... \_\_\_\_\_  
Amendment Including Elections

ABST \_\_\_\_\_  
Abstract

ADS \_\_\_\_\_  
Application Data Sheet

AF/D \_\_\_\_\_  
Affidavit or Exhibit Received

APPENDIX \_\_\_\_\_  
Appendix

ARTIFACT \_\_\_\_\_  
Artifact

BIB \_\_\_\_\_  
Bib Data Sheet

CLM \_\_\_\_\_  
Claim

COMPUTER \_\_\_\_\_  
Computer Program Listing

CRFL \_\_\_\_\_  
All CRF Papers for Backfile

DIST \_\_\_\_\_  
Terminal Disclaimer Filed

DRW \_\_\_\_\_  
Drawings

FOR \_\_\_\_\_  
Foreign Reference

FRPR \_\_\_\_\_  
Foreign Priority Papers

IDS \_\_\_\_\_  
IDS Including 1449

NPL \_\_\_\_\_  
Non-Patent Literature

OATH \_\_\_\_\_  
Oath or Declaration

PET. \_\_\_\_\_  
Petition

RETMAIL \_\_\_\_\_  
Mail Returned by USPS

24/07/02 SEQLIST 3  
Sequence Listing

SPEC \_\_\_\_\_  
Specification

SPEC NO \_\_\_\_\_  
Specification Not in English

TRNA \_\_\_\_\_  
Transmittal New Application

CTNF \_\_\_\_\_  
Count Non-Final

CTRS \_\_\_\_\_  
Count Restriction

EXIN \_\_\_\_\_  
Examiner Interview

M903 \_\_\_\_\_  
DO/EO Acceptance

M905 \_\_\_\_\_  
DO/EO Missing Requirement

NFDR \_\_\_\_\_  
Formal Drawing Required

NOA \_\_\_\_\_  
Notice of Allowance

PETDEC \_\_\_\_\_  
Petition Decision

## OUTGOING

CTMS \_\_\_\_\_  
Misc. Office Action

1449 \_\_\_\_\_  
Signed 1449

892 \_\_\_\_\_  
892

ABN \_\_\_\_\_  
Abandonment

APDEC \_\_\_\_\_  
Board of Appeals Decision

APEA \_\_\_\_\_  
Examiner Answer

CTAV \_\_\_\_\_  
Count Advisory Action

CTEQ \_\_\_\_\_  
Count Ex parte Quayle

CTFR \_\_\_\_\_  
Count Final Rejection

## INCOMING

AP.B \_\_\_\_\_  
Appeal Brief

C.AD \_\_\_\_\_  
Change of Address

N/AP \_\_\_\_\_  
Notice of Appeal

PA.. \_\_\_\_\_  
Change in Power of Attorney

REM \_\_\_\_\_  
Applicant Remarks in Amendment

XT/ \_\_\_\_\_  
Extension of Time filed separate

### Internal

SRNT \_\_\_\_\_  
Examiner Search Notes

CLMPTO \_\_\_\_\_  
PTO Prepared Complete Claim Set

ECBOX \_\_\_\_\_  
Evidence Copy Box Identification

WCLM \_\_\_\_\_  
Claim Worksheet

WFEE \_\_\_\_\_  
Fee Worksheet

### File Wrapper

FWCLM \_\_\_\_\_  
File Wrapper Claim

IIFW \_\_\_\_\_  
File Wrapper Issue Information

SRFW \_\_\_\_\_  
File Wrapper Search Info



#5

## SEQUENCE LISTING

<110> Focke, Margarete  
Mahler, Vera  
Sperr, Wolfgang R.  
Valent, Peter  
Kraft, Dietrich  
Valenta, Rudolf

<120> Allergy Vaccines and Their Preparation

<130> 0273-0005

<140>

<141> 2001-12-27

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
solvent-exposed peptide

<400> 1

Met Gly Val Phe Asn Tyr Glu Thr Glu Thr Thr Ser Val Ile Pro Ala  
1 5 10 15

Ala Arg Leu Phe Lys Ala Phe Ile Cys  
20 25

<210> 2

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
solvent-exposed peptide

<400> 2

Leu Phe Pro Lys Val Ala Pro Gln Ala Ile Ser Ser Val Glu Asn Ile  
1 5 10 15

Glu Gly Asn Gly Gly Pro Gly Thr Ile Lys Lys Ile Ser Phe Cys  
20 25 30

<210> 3

<211> 31

<212> PRT